Avenue Therapeutics, Inc.
ATXI
$0.773
-$0.1725-18.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 829.00K | 1.46M | 1.32M | 1.14M | 1.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.16M | 2.82M | 3.71M | 2.12M | 2.07M |
| Operating Income | -3.16M | -2.82M | -3.71M | -2.12M | -2.07M |
| Income Before Tax | -3.09M | -2.70M | -4.35M | 617.00K | 513.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.09M | -2.70M | -4.35M | 617.00K | 513.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 11.00K | 9.00K | 9.00K | 23.00K | 13.00K |
| Net Income | -3.08M | -2.69M | -4.34M | 640.00K | 526.00K |
| EBIT | -3.16M | -2.82M | -3.71M | -2.12M | -2.07M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.92 | -6.43 | -15.40 | 2.30 | 4.86 |
| Normalized Basic EPS | -1.20 | -1.50 | -4.82 | 1.47 | 3.08 |
| EPS Diluted | -1.92 | -6.43 | -15.40 | 2.30 | 4.86 |
| Normalized Diluted EPS | -1.20 | -1.50 | -4.82 | 1.47 | 3.08 |
| Average Basic Shares Outstanding | 1.60M | 1.12M | 562.00K | 278.70K | 108.20K |
| Average Diluted Shares Outstanding | 1.60M | 1.12M | 562.00K | 278.70K | 108.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
